Technical Analysis for BOLT - Bolt Biotherapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 0.66 | 3.75% | 0.02 |
BOLT closed up 3.75 percent on Friday, November 1, 2024, on 17 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Nov 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| NR7 | Range Contraction | 3.75% | |
| Narrow Range Bar | Range Contraction | 3.75% | |
| Down 3 Days in a Row | Weakness | 3.75% | |
| Down 4 Days in a Row | Weakness | 3.75% | |
| Gapped Down | Weakness | 3.75% | |
| Fell Below 20 DMA | Bearish | 2.14% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 21 hours ago |
| 50 DMA Support | about 21 hours ago |
| 60 Minute Opening Range Breakdown | about 22 hours ago |
| 50 DMA Resistance | about 22 hours ago |
| 20 DMA Resistance | about 22 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/07/2024
Bolt Biotherapeutics, Inc., a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors. Its preclinical stage product candidates include carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade; and myeloid modulators. Bolt Biotherapeutics, Inc. was founded in 2015 and is based Redwood city, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Tumor Pharmaceutical Products Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Tumor Pharmaceutical Products Cancer Immunotherapy Breast Cancer Immune Checkpoint Her2/Neu
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.56 |
| 52 Week Low | 0.545 |
| Average Volume | 144,678 |
| 200-Day Moving Average | 0.89 |
| 50-Day Moving Average | 0.64 |
| 20-Day Moving Average | 0.65 |
| 10-Day Moving Average | 0.66 |
| Average True Range | 0.04 |
| RSI (14) | 53.49 |
| ADX | 13.65 |
| +DI | 19.45 |
| -DI | 14.51 |
| Chandelier Exit (Long, 3 ATRs) | 0.61 |
| Chandelier Exit (Short, 3 ATRs) | 0.71 |
| Upper Bollinger Bands | 0.68 |
| Lower Bollinger Band | 0.62 |
| Percent B (%b) | 0.67 |
| BandWidth | 9.69 |
| MACD Line | 0.00 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0008 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.68 | ||||
| Resistance 3 (R3) | 0.68 | 0.67 | 0.68 | ||
| Resistance 2 (R2) | 0.67 | 0.66 | 0.67 | 0.68 | |
| Resistance 1 (R1) | 0.66 | 0.66 | 0.67 | 0.67 | 0.68 |
| Pivot Point | 0.65 | 0.65 | 0.66 | 0.66 | 0.65 |
| Support 1 (S1) | 0.65 | 0.65 | 0.65 | 0.65 | 0.64 |
| Support 2 (S2) | 0.64 | 0.64 | 0.64 | 0.64 | |
| Support 3 (S3) | 0.63 | 0.64 | 0.64 | ||
| Support 4 (S4) | 0.64 |
